Group 1 - The core viewpoint of the articles highlights the continued high demand for Chinese innovative drugs in global markets, with significant business development (BD) transactions occurring in early 2026, indicating a strong growth trajectory for the industry [1][2]. - As of February 15, 2026, there have been 39 license-out transactions for Chinese innovative drugs, with an upfront payment of approximately $2.953 billion and a total value exceeding $49 billion, surpassing one-third of the total amount for 2025 [1]. - Morgan Stanley's report emphasizes a positive long-term outlook for the Chinese pharmaceutical industry, identifying "catalysts" as a key theme, with expectations for numerous catalysts in 2026 that will enhance the global value of domestic pharmaceutical assets [2]. Group 2 - Morgan Stanley specifically mentions that 2025 saw a total BD transaction amount of $135.7 billion for Chinese innovative drugs, surpassing the U.S. for the first time, with 2026 showing even stronger growth as the first 49 days of transactions exceeded any single quarter in 2025 [2]. - The report highlights Hengrui Medicine as a preferred investment target, predicting accelerated sales growth in 2026 and a positive trend in new cooperative transactions, which are crucial for realizing milestone payments [2]. - The transformation of Kangzhe Pharmaceutical towards innovative drugs is noted, with the approval of a targeted drug for vitiligo, indicating a significant step in the company's transition and growth strategy [3]. Group 3 - Despite the ongoing BD transaction boom, the innovative drug sector is experiencing a market downturn, with the Hong Kong innovative drug ETF dropping 0.78% after the Spring Festival, indicating a disconnect between market sentiment and fundamentals [4]. - The focus of BD transactions in 2026 is shifting towards early-stage research projects, with over 50% of the 39 transactions being in preclinical stages, reflecting a strategic pivot in the industry [5]. - Companies like Kangfang Biotech are optimistic about the global impact of Chinese innovative drugs, aiming to expand their global footprint and enhance their international presence in drug development [5].

Core Insights - China's innovative drug sector continues to thrive, with significant business development (BD) transactions occurring in early 2026, indicating strong global recognition of Chinese innovation [1][2] - Morgan Stanley's report highlights the long-term potential of China's pharmaceutical industry, emphasizing the importance of globalization and industry differentiation [1][2] Group 1: Business Development Transactions - As of February 15, 2026, there have been 39 license-out transactions in China's innovative drug sector, with upfront payments totaling approximately $2.953 billion and total transaction values exceeding $49 billion [1] - In 2025, the total BD transaction amount for Chinese innovative drugs reached $135.7 billion, surpassing that of the United States for the first time [2] - The first 49 days of 2026 have already seen transaction volumes exceed any single quarter in 2025, reflecting a robust growth trend [2] Group 2: Key Companies and Developments - Morgan Stanley identifies Heng Rui Medicine as a top pick, expecting accelerated sales growth and positive momentum in new cooperative transactions for 2026 [2] - The approval of the innovative drug, phosphor-lucotidine cream, by Kangzhe Pharmaceutical marks a significant milestone, being the first targeted drug for vitiligo in China [2] - Kangzhe Pharmaceutical's planned spin-off of its subsidiary, Demai Pharmaceutical, for a Hong Kong listing is seen as a strategic move to focus on core therapeutic areas while potentially enhancing short-term profitability [3] Group 3: Market Trends and Future Outlook - The innovative drug sector is experiencing a clear division, with companies reliant on generic drugs facing performance pressures, while those with sustainable innovation capabilities are positioned for high-quality growth [3][4] - The current BD trend is shifting towards early-stage research projects, with over 50% of recent transactions involving preclinical projects [5] - Companies like Kangfang Biotech are committed to expanding their global footprint and enhancing the international visibility of Chinese innovations in drug development [5]

Investment Rating - The report does not explicitly state an investment rating for the dry eye disease treatment industry Core Insights - The dry eye disease market in China is experiencing significant growth, with the number of patients increasing from 300 million in 2020 to 360 million in 2024, representing a compound annual growth rate (CAGR) of approximately 5% [7] - The treatment rate for dry eye disease remains low at 10%-12%, indicating substantial market potential [3] - The market is evolving from traditional artificial tears to innovative therapies, including preservative-free formulations and new drug delivery systems, driven by advancements in formulation technology [3] - Local pharmaceutical companies are making breakthroughs in anti-inflammatory mechanisms and targeted therapies, leading to a new competitive landscape focused on innovative drugs and precision treatment [3] Market Background - The dry eye disease market has evolved through three stages: the nascent stage (1995-2005), the initiation stage (2006-2015), and the rapid development stage (2016-present) [5][6] - The current market is characterized by a shift from foreign dominance to a competitive landscape involving both domestic and foreign companies [12] Market Status - The market size is projected to reach 139 billion yuan in 2024, with expectations to grow to 193 billion yuan by 2030, reflecting a CAGR of about 9% [7] - The supply chain includes high-activity raw materials and a diverse range of products, with foreign companies currently holding a significant market share in artificial tears [8] - Demand for treatments is increasing, particularly among moderate to severe dry eye patients who require combination therapies [9] Market Competition - The competitive landscape is marked by a clear tiered structure, with leading companies like Santen Pharmaceutical and domestic firms like Xingqi Eye Medicine dominating the first tier [12] - The report identifies ten key brands in the market, highlighting their strengths and market positions [13] - Domestic companies are increasingly closing the gap with foreign firms through innovation and strategic partnerships [12] Development Trends - The market is expected to maintain a growth rate of around 9% from 2025 to 2030, driven by advancements in diagnostic technologies and innovative therapies [27] - Drug innovation is diversifying, with traditional drugs being upgraded and new treatment modalities emerging [28] - Local companies are expanding globally, with firms like Heng Rui Medicine and Xingqi Eye Medicine leading the charge in international markets [29]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice from the National Medical Products Administration regarding the acceptance of its drug listing application for the innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), developed independently by Heng Rui Medicine [1] - The mechanism of SHR-1918 involves inhibiting the activity of ANGPTL3 to lower serum triglycerides (TG) and LDL-C levels [1] - The proposed indication for SHR-1918 is for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia [1]

Group 1 - Hengyu Environmental reported a revenue of 294 million yuan for 2025, an increase of 89.87%, and a net profit of 35.93 million yuan, up 106.25% year-on-year [1] - Yongxi Electronics achieved a revenue of 4.4 billion yuan in 2025, a growth of 21.92%, with a net profit of 82.24 million yuan, reflecting a year-on-year increase of 23.99% [2] - Zhongwei Semiconductor reported a revenue of 1.122 billion yuan for 2025, a 23.09% increase, and a net profit of 285 million yuan, up 108.05% year-on-year [3] - Sry New Materials achieved a revenue of 1.564 billion yuan in 2025, a growth of 17.66%, with a net profit of 154 million yuan, reflecting a year-on-year increase of 35.04% [14] - Jiaokong Technology reported a revenue of 2.537 billion yuan for 2025, a growth of 16.08%, and a net profit of 156 million yuan, up 86.13% year-on-year [15] - SanSheng Guojian reported a revenue of 4.199 billion yuan for 2025, a significant increase of 251.81%, with a net profit of 2.939 billion yuan, up 317.09% year-on-year [30] Group 2 - Aidi Pharmaceutical reported a revenue of 721 million yuan for 2025, a growth of 72.49%, but incurred a net loss of 19.73 million yuan, reducing losses from 142 million yuan in the previous year [5] - Weidao Nano reported a revenue of 2.632 billion yuan for 2025, a decrease of 2.52%, with a net profit of 213 million yuan, down 6.12% year-on-year [9] - Wens Foodstuff Group reported a revenue of 103.884 billion yuan for 2025, a decline of 1.67%, with a net profit of 5.235 billion yuan, down 43.59% year-on-year [29] - Supor reported a revenue of 22.772 billion yuan for 2025, a growth of 1.54%, with a net profit of 2.097 billion yuan, down 6.58% year-on-year [33] Group 3 - ShaoNeng Co. signed a significant operational contract worth 22 million yuan for a biomass power generation project [6] - Shunlian Bio plans to use 237 million yuan to acquire controlling interest in a joint venture, increasing its stake from 16.99% to 51% [7] - Huason Pharmaceutical's subsidiary received clinical trial approval for an innovative drug, indicating progress in its product pipeline [8] - Xinyang Technology's subsidiary received a medical device registration certificate, enhancing its product offerings [10][11] - Yida Co. obtained an investment project filing certificate for a chemical production project with a total investment of 642 million yuan [12]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1: Product Development - SHR-1918 injection is a monoclonal antibody targeting angiopoietin-like protein 3 (ANGPTL3), aimed at reducing serum triglycerides (TG) and LDL-C levels [1] - The total R&D investment for the SHR-1918 injection project has reached approximately 242.2 million yuan (unaudited) [1] Group 2: Market Context - The only other drug targeting the same pathway is Regeneron's EVKEEZA® (evinacumab-dgnb), which has been approved and is projected to generate global sales of approximately $216 million by 2025 [1]

Group 1 - The core point of the article is that Heng Rui Medicine (01276.HK) announced that its subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a "Notice of Acceptance" from the National Medical Products Administration for its innovative drug SHR-1918 injection, which has been accepted for review and included in the priority review process [1] Group 2 - The drug SHR-1918 is classified as a Class 1 innovative drug, indicating its potential significance in the pharmaceutical market [1] - The inclusion in the priority review process suggests that the regulatory body recognizes the drug's importance and aims to expedite its approval [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Beijing Shengdi Pharmaceutical Co., Ltd., has received a notice of acceptance from the National Medical Products Administration for the marketing authorization application of its innovative drug SHR-1918 injection, which has been included in the priority review process [1] Group 1 - The application for market approval is based on two clinical trials targeting patients with Homozygous Familial Hypercholesterolemia (HoFH): SHR-1918-202 and SHR-1918-301, led by Professor Peng Daoquan from Central South University Xiangya Second Hospital [2] - The SHR-1918-202 study is a Phase II multicenter, single-arm trial conducted in adult HoFH patients, with results published in the Journal of the American College of Cardiology, showing an average reduction of 59.1% in serum low-density lipoprotein cholesterol (LDL-C) with a significant absolute reduction of 6.6 mmol/L, indicating substantial and sustained LDL-C level reduction with good safety and tolerability [2] - The SHR-1918-301 study is a randomized, double-blind, placebo-controlled Phase III clinical trial involving HoFH patients aged 12 and older, conducted across 16 clinical research centers nationwide, with lipid-lowering efficacy characteristics highly consistent with the SHR-1918-202 study results and good safety [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2026年2月24日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，江苏恒瑞医药股份有限公司（以下简称"公司"）子公司北京盛迪医 药有限公司收到国家药品监督管理局（以下简称"国家药监局"）下发的《受理 通知书》，公司 1 类 ...

Core Viewpoint - Heng Rui Medicine emphasizes its commitment to a technology innovation strategy, expanding its product pipeline to address unmet clinical needs in chronic disease management while continuing to deepen its focus on oncology [1] Group 1: R&D Strategy - The company is broadening its research and development efforts beyond oncology to include metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [1] - Several innovative products have already been approved for market, targeting conditions such as type 2 diabetes, atopic dermatitis, psoriasis, rheumatoid arthritis, ankylosing spondylitis, and hypercholesterolemia [1] Group 2: Product Pipeline - The company has a diverse pipeline with dozens of new drugs currently in clinical development [1]